1. Introduction
===============

Many nonspecific viral inhibitors from body fluids and tissues have been described, but most are active against only a few viruses ([@BIB14], [@BIB18], [@BIB13], [@BIB3], [@BIB16], [@BIB15], [@BIB25], [@BIB11]). Of particular interest are the broadly active viral inhibitors ([@BIB17], [@BIB1], [@BIB4], [@BIB5], [@BIB20], [@BIB21], [@BIB22]) as they could be of importance in affording natural protection against many viral infections ([@BIB7]) and in medical use. The purpose of this study was to determine the properties of the broadly active inhibitors associated with the gastrointestinal (GI) tract, including size, structure, active chemical moiety and mechanisms of action. Other broadly active viral inhibitors have been reported in certain body tissues and fluids ([@BIB20], [@BIB21], [@BIB22]). The other inhibitors include high-density lipoprotein in plasma ([@BIB22]), UTIB in plasma ([@BIB20]) and NS inhibitor, which is distributed throughout the central and peripheral nervous systems ([@BIB21]). These other inhibitors are distinct from the present GI inhibitor as determined by their properties and mechanisms of antiviral action. These findings with the GI inhibitors are compared to the properties of the other innate inhibitors that were reported previously in various body tissues and fluids.

2. Materials and methods {#SEC2}
========================

2.1. Inhibitors
---------------

Porcine mucosal, neuramide and mouse intestinal inhibitors were used. The porcine mucosal preparation (National Formulary XII specifications) was obtained from American Laboratories (Omaha, NE). The porcine preparation was dissolved in Eagle\'s minimum essential medium (EMEM) at a ratio of 1.7 ml per g of original net weight. Antiviral activity is expressed as units/ml of this solution. Neuramide is a partially purified proprietary extract of gastric mucosa and milk, which is used medically to treat viral infection in humans. The starting material is clarified, heated, and extracted with lipid solvents. It was obtained from DIFA-Cooper, Milan, Italy as a clear, tan-colored solution that was not processed further before use.

The mouse intestinal inhibitor preparation was made from the intestines isolated from 20 g ICR female mice, Harlan Sprague--Dawley, Houston, TX. The intestines were washed in Hank\'s balanced salt solution (HBSS) and one set of samples (2 ml/g of intestine) was prepared by flushing medium through the lumen. The other set was minced, washed three times, and suspended in medium, two times the volume of their weight at 4°C for 24 h. The preparations were vortexed thoroughly and centrifuged at 2000 rev./min for 10 min. The supernatant was centrifuged at 15 000 rev./min for 20 min and filtered through 0.45- and 0.22-μm Corning 50-ml filters. The filtrate was aliquoted in 5-ml amounts and stored at −20°C until use. The two preparations had equal antiviral activity. The eluate from the minced and washed preparation was used for characterization. Thus for these initial characterization studies, centrifuged and filtered inhibitor preparations were used to initially establish their major properties. All experiments were performed at least two times and often four times.

2.2. Antiviral assay
--------------------

Antiviral titers of the inhibitors were determined by the 50% virus plaque reduction assay, previously described ([@BIB2]). The viruses used were: a poxvirus, vaccinia (IHDE strain); a herpes virus, herpes simplex I (Heitzman strain); enteroviruses, poliomyelitis type I (Mahoney strain) and mengovirus (MV), an alphavirus, Sindbis (EgAr 339 strain) (SBV); a bunyavirus, Bunyamwera (original strain); and a rhabdovirus, vesicular stomatitis (Indiana strain) (VSV). These viruses were originally obtained from the National Institute of Health (Bethesda, MD), and have since been maintained in our laboratory ([@BIB17], [@BIB1], [@BIB20]). Vero cells (African green monkey kidney cells, American Type Culture Collection, CCL 81) were used for assaying the inhibitors. The antiviral activity was expressed as units per ml. One unit (U) was determined as the reciprocal of the highest dilution of inhibitor preparation showing 50% inhibition of 30--40 plaque-forming units (PFU) used for challenge. All assays included at least two replicates and results were confirmed in repeated experiments. Neuramide was used as a positive virus inhibitor control in each assay.

2.3. Molecular size
-------------------

Molecular sizing of neuramide and mouse intestine inhibitors was performed on soft-gel and high performance liquid chromatography (HPLC) supports. Preliminary determinations were performed on calibrated 1.0×50.0 cm Bio-Gel P-6 (Bio-Rad) columns equilibrated with 50 mM Tris--HCl, pH 7.5. UV absorbance was monitored at 280 nm, and 1.0-ml fractions were collected. Fractions were assayed for antiviral activity. These results were confirmed by HPLC on two SynChropak GPC Peptide columns (7.8×300 mm, SynChrom, Lafayette, IN) connected in series. Filtered and centrifuged samples of 0.5 ml were applied to the columns, which were run in 0.1 M sodium phosphate buffer, pH 7.2. Fractions of 1 ml were collected and assayed for antiviral activity.

2.4. Chemical composition
-------------------------

Chemical composition of inhibitors was investigated by lipid extraction and enzymatic degradation. To determine the effect of lipid extraction, an inhibitor sample was extracted five times with an equal amount of *n*-butanol and two times with ethyl ether ([@BIB21]). Organic and aqueous phases were separated, and the residual organic solvents were removed from the aqueous phase by evaporation in a Speedvac AES 1000 (Savant Instruments, Inc., Farmingdale, NY) before assaying for antiviral activity.

The effect of proteolysis was determined by using immobilized proteinase K (Sigma, St Louis, MO) ([@BIB20]). Briefly, 1 ml of inhibitor sample, preadjusted to pH 7.5, was incubated with 30 mg proteinase K after hydration at 37°C for 4 h in a rotary shaker. The enzyme beads were removed by centrifugation, and the supernatant was assayed for antiviral activity.

The role of complex carbohydrates as an essential structure in antiviral activity was determined by periodate oxidation and enzymatic deglycosylation ([@BIB20]). Briefly, the periodate oxidation was achieved by adding 0.35 M NaIO~4~ to the inhibitor sample (pH 7.5) and incubating at 37°C for 24 h. The sample was dialyzed against a 100 molecular weight cut off (MWCO membrane) to remove NaIO~4~ and assayed for antiviral MWCO membrane activity. Control experiments showed that IO~4~, although slightly larger than 100 Dalton, did pass through the membrane entirely, presumably due to a tolerance range that included IO~4~. Deglycosylation was performed by a modified technique of [@BIB8] ([@BIB20]) by treating the inhibitor with a mixture of carbohydrases, consisting of α-galactosidase (Boehringer Mannheim, Indianapolis, IN); β-*N*-acetylglucosaminidase (Sigma, St Louis, MO); endoglycosidase (Sigma); neuraminidase (Sigma); and β-mannosidase (Sigma). The inhibitor sample preadjusted to pH 6.0 was mixed with 100 μl of the glycosidase mixture and incubated at 37°C in a rotary shaker for 24 h. To it was then added a sulfhydryl reducing agent, dithiothreitol (DTT), in a final concentration of 0.1 M, and the mixture was further incubated for 6 h. We modified the procedure by omitting DTT for the mouse intestinal inhibitor, since at this point we had found the small size of this inhibitor and unfolding of small molecule is not required for penetration by glycosidases. Samples containing DDT were dialyzed to remove the DTT and assayed for residual antiviral activity ([@BIB20], [@BIB21]).

2.5. Mechanism of inhibition
----------------------------

The mechanism of action of inhibitors was studied by investigating whether or not the antiviral activity is due to (1) directly reversible neutralization of virions, (2) inhibition of virus attachment to cells, (3) inhibition of virus replication post-attachment to cells, or (4) induction of antiviral activity in the target cells as described below.

To test the ability of the inhibitor to irreversibly neutralize virus was determined as previously described ([@BIB17]), using a plaque reduction assay with each of the viruses. Twenty-four to 64 U/ml of inhibitor and 10^3.8^ PFU of virus were mixed and incubated at 37°C for 2 h. The mixture was diluted beyond the inhibitory titer of the inhibitor and assayed for recovery of residual infectious virus.

The effect of the inhibitors on the attachment of Sindbis (SBV), vesicular stomatitis (VSV), and mengoviruses (MV) was examined by comparing the inhibitory titers at 4°C for 2 h (virus attachment, but not penetration, can occur at this temperature) with 37°C (virus attachment and penetration) ([@BIB17], [@BIB20]). The effective virus challenge was 40 PFU (MOI=0.03) which was allowed to infect the confluent Vero cells in a 96-well microtiter plate. The cultures were then washed three times and overlaid with 50 μl of 0.5% methylcellulose in Hepes buffer and culture medium (MC). Plaques were stained with crystal violet and read on day 2.

The time during the virus growth cycle at which virus replication was inhibited was determined as described previously ([@BIB21]). Inhibitor (20 U/ml) was added at various times to a timed one-step growth cycle of the virus, and virus yield was determined at the end of a single cycle of growth by harvesting virus at 8 h. Synchronized initiation of virus replication (designated 0 h) was obtained by infecting cell monolayers with 10^3.8^ PFU (MOI=0.16) of virus in 96-well cell culture plates at 4°C for 2 h to allow virus attachment. The cells were then washed three times with cold EMEM to remove unabsorbed virus and inhibitor and then refed with warm (37°C) inhibitor of EMEM containing 2% FBS. After incubation for a total of 8 h (a single cycle virus at 37°C replication) the cultures were stored at −70°C. The virus yield from quadruplicate wells was pooled for virus plaque assay. The virus yield was determined by titration of PFU on Vero cells.

At the virus dilutions used, inactive virus is in low concentration and the time of its production of any interferon would be too late to influence the single growth cycle.

The possible induction of an antiviral state in cells, e.g. like interferon (IFN), by inhibitors was determined as described previously ([@BIB20]). The confluent monolayers of Vero cells were incubated overnight with serial dilutions of the inhibitor preparation to allow any antiviral activity to develop in the cells, washed three times with EMEM to remove any non-cell associated inhibitory activity, and challenged with 40 PFU of virus. After 2 h of incubation the cells were overlaid with 0.5% MC. The 50% plaque reduction end point was calculated.

3. Results
==========

3.1. Molecular size
-------------------

All three sample types were tested on a variety of size exclusion columns. The antiviral activity consistently emerged in the column volume for most supports, indicating that the active moiety was of very small size. On calibrated P-6 columns, the activity began to separate from the salt peak, but gave inconclusive results. On the Synchropak GPC peptide HPLC columns, which are able to resolve small peptides, the neuramide, porcine mucosal, and mouse intestinal inhibitors all emerged with an apparent molecular size of \<1000 Da. This is consistent with results of dialysis experiments, where the antiviral activity is unretained by all but the smallest (100 Da MWCO) membranes. Based on the GPC peptide results, we assign a tentative molecular weight of 600±400 Da to the antiviral moiety in these preparations.

3.2. Antiviral spectrum
-----------------------

To determine the breadth of antiviral activity, the three gastrointestinal extracts were assayed for antiviral activity against five viruses. The antiviral activity of all three gastrointestinal inhibitors was broad in that all of the viruses tested, including a DNA virus and enveloped and nonenveloped RNA viruses were inhibited ([Table 1](#TBL1){ref-type="table"} ). The titers of the inhibitors were substantial, ranging from 24 to 64 U/ml. Statistically, there were no significant differences in antiviral activity when the inhibitors were compared. The small molecular weight dialysates through 10 000 MW membranes had the same broad activity, but the retentates were inactive. Control preparations from kidney and liver tissue gave titers of \<10 U/ml, and medium controls were negative. Thus, all three gastrointestinal extracts contained significant titers of broadly antiviral substance(s).Table 1Antiviral spectrum of porcine mucosal, neuramide, and mouse intestinal virus inhibitorsSampleAntiviral activity (U/ml)[a](#TBLFN1){ref-type="table-fn"}SB[b](#TBLFN2){ref-type="table-fn"}VSVACMengoHSVIPorcine mucosa[c](#TBLFN3){ref-type="table-fn"}6464644896Neuramide[c](#TBLFN3){ref-type="table-fn"}4864484848Mouse intestine[c](#TBLFN3){ref-type="table-fn"}2424324832[^1][^2][^3]

3.3. Chemical composition required for antiviral activity
---------------------------------------------------------

To determine the structural composition required for antiviral activity, the extracts were treated to degrade proteins, break carbohydrate linkages, oxidize carbohydrates, or extract lipids and then the residual antiviral activity was measured. Treatment of neuramide, porcine mucosal and mouse intestine preparations, with either proteinase K, carbohydrases, sodium periodate, or extraction by lipid solvents (butanol and ethyl ether), did not affect their antiviral activity ([Table 2](#TBL2){ref-type="table"} ). Since the carbohydrases would not degrade all possible sugar linkages expected to be present in the GI tract, we also treated with NaIO~4~ as a general oxidizing agent with negative results. Previously, both treatments appropriately inactivated the other antiviral inhibitors in body tissues and fluids in our laboratory ([@BIB20], [@BIB21]). These findings with the intestinal preparations suggest that protein, carbohydrate, and lipid moieties may not be required for the antiviral activity of GI inhibitors.Table 2Glycolysis, proteolysis and lipid extraction do not inactivate the antiviral activity of porcine mucosal extract, neuramide and mouse intestine inhibitorsSampleAntiviral activity (U/ml)[a](#TBLFN4){ref-type="table-fn"}Periodate oxidationGlycolysisProteolysisLipid extractionInitialFinalInitialFinalInitialFinalInitialFinalPorcine mucosa168146694332242828Neuramide11280485624202020Mouse intestineND[b](#TBLFN5){ref-type="table-fn"}ND91720192215[^4][^5]

3.4. Mechanism of action
------------------------

To determine whether the intestinal preparations directly inactivated viruses, viruses were pretreated with 24--64 U/ml of each inhibitor and then assayed for residual infectivity titer. Pretreatment of SBV, VSV, and MV with neuramide, porcine mucosal extract, and mouse intestine inhibitors did not change their infectivity titers significantly (data not shown). This indicated that they did not bind irreversibly to virions to permanently neutralize the infectivity, as would neutralizing antibody.

To determine whether the inhibitors acted during attachment, or later in the replication cycle, the inhibitory titers of inhibitors were compared at 4 and 37°C. The rationale for the temperature experiment is that at 4°C the cell membrane is physiologically inert, and hence virus replication should not proceed beyond initial attachment to the target cell. Comparable titers at 4 and 37°C, therefore, imply that an antiviral substance inhibits the attachment of virus to target cells. Significantly higher titers at 37 than at 4°C imply that the inhibitor acts at a post-attachment stage. [Table 3](#TBL3){ref-type="table"} shows that the titers of neuramide and porcine mucosal inhibitors against SBV, VSV and MV at 4°C were significantly lower than those assayed at 37°C. This indicates that neuramide and porcine mucosal inhibitors may act by blocking viral replication at a post-attachment stage. The mouse intestine inhibitor, on the other hand, is active at 4°C, and, therefore, inhibits virus replication by preventing attachment of virions to the target cells.Table 3Activity of porcine mucosal, neuramide, and mouse intestinal virus inhibitors at 4°CSampleAntiviral activity (U/ml)[a](#TBLFN6){ref-type="table-fn"}SB[b](#TBLFN7){ref-type="table-fn"}VSMengo37°C4°C37°C4°C37°C4°CPorcine mucosa704[c](#TBLFN8){ref-type="table-fn"}543[c](#TBLFN8){ref-type="table-fn"}574[c](#TBLFN8){ref-type="table-fn"}Neuramide63\<3[c](#TBLFN8){ref-type="table-fn"}51\<2[c](#TBLFN8){ref-type="table-fn"}65\<2[c](#TBLFN8){ref-type="table-fn"}Mouse intestine14878814[^6][^7][^8]

To further determine when the inhibitor acted in the virus growth cycle, we carried out timed-addition of inhibitors in a single-cycle, yield-reduction experiment. Specifically, we determined virus yields after addition of inhibitor preparations to infected cell monolayers at various times after synchronous infection. Virus titers were measured after a single growth cycle (8 h) to avoid possible complications stemming from suppression of subsequent growth cycles by residual inhibitor. As shown in [Fig. 1](#FIG1){ref-type="fig"} , when the inhibitor preparations were added at 0 h and left in the culture, they reduced the yield of SBV by 98--99%. When the inhibitors were added 1--6 h later, only the porcine mucosal inhibitor reduced the yield of SBV. Thus, the porcine mucosal inhibitor caused the inhibition of virus replication after attachment of the virus to the cell for as long as 6 h after initiation of the growth cycle. In comparison, in the presence of the mouse intestine inhibitor and the neuramide, this inhibition occurred only at 0 h, indicating inhibition either during attachment (intestinal inhibitor) or early post-attachment (neuramide). Thus, these observations are consistent with the 4°C experiment, and will be discussed later.Fig. 1Timed addition of porcine mucosal, neuramide, and mouse intestinal preparations during a single cycle replication of Sindbis virus. The inhibitor preparations were applied at various times to Vero cells after infection with 10^4--5^ PFU of Sindbis virus. The culture fluid was harvested at 8 h, the end of a single-cycle of virus multiplication. The reduction of the virus yield by different inhibitors is plotted to the level of 65%, because inhibition below this point was not statistically significant. \**P*\<0.05 by the Student *t*-test.

To determine if cells acquired resistance to virus infection after pretreatment with inhibitor, they were incubated with the inhibitor preparations (mouse intestine, neuramide and porcine mucosa) for 24 h and then washed before virus challenge. The pretreated cells did not exhibit any resistance to subsequent infection to SBV, VSV or MV (data not shown), indicating that unlike interferon, the inhibitors do not induce a durable antiviral state in the target cells.

4. Discussion
=============

Generally in most viral infections, specific immunity is preceded by innate non-specific defenses ([@BIB4], [@BIB6]). Specific immunity generally begins on day 5--7 post viral infection, but the virus multiplication starts decreasing earlier, that is, 3--5 days post infection ([@BIB4], [@BIB6]). The early decrease of virus has been attributed to interferon, inflammation and innate viral inhibitors ([@BIB3]).

The antiviral activities of innate inhibitors against individual or families of viruses are reported to reside in a variety of uncharacterized or partly characterized substances. Most are distinguishable from antibody, interferon, and complement. Many of the antiviral substances have generally been reported to act against single viruses, such as some coronaviruses, Newcastle disease virus, variola virus, Sendai virus, and vesicular stomatitis virus ([@BIB14], [@BIB15], [@BIB25], [@BIB23], [@BIB11]). Some are active against individual virus families, including myxoviruses, togaviruses, and retroviruses ([@BIB16], [@BIB19], [@BIB27]). The mechanisms of action of these viral inhibitors, when known, vary. Some of these act by irreversible neutralization of infectivity, as in the case with coronavirus and Sendai virus inhibitors ([@BIB14], [@BIB15], [@BIB23], [@BIB11]). The myxo- and togavirus inhibitors appear to prevent hemaglutination but not infectivity ([@BIB16], [@BIB19]). The inhibitor of vesicular stomatitis virus acts by penetration of the viral envelope and inactivation of viral RNA ([@BIB25]). The retrovirus inhibitor works via complement-mediated lysis of the virally infected cells ([@BIB27]).

Among the innate non-specific viral inhibitors present in various tissues, the broadly active inhibitors are of specific interest for the present study, because they may function to prevent infection by many viruses ([@BIB20], [@BIB7]). Some of the broadly active non-specific viral inhibitors present in plasma and nervous system from humans, rabbits and mice ([@BIB1]) have been characterized ([@BIB20], [@BIB21], [@BIB22]). In vivo, a protective role of the nervous tissue inhibitor against viral infection, has been shown ([@BIB7]). In the GI tract, an inhibitor was also found in mice, rabbits, and humans but was not fully characterized ([@BIB1]). The present study was done to further characterize the essential structures of the GI inhibitors from murine and porcine origin. Our studies show that mouse intestine, porcine mucosal inhibitor and neuramide preparations are active against a number of DNA and RNA viruses and have antiviral activity in the range of 24--96 U/g or ml ([Table 1](#TBL1){ref-type="table"}). They all have a molecular size of 600±400 Da and appear to be resistant to lipid solvents, proteolysis and glycolysis.

The resistance to degradation by the GI inhibitors could be of significance in vivo, since to remain active in the GI tract, the inhibitors must resist the action of the various lipolytic, proteolytic and glycolytic activities of the digestive process. An interesting possibility is that antivirally defensive molecules have evolved to be resistant to digestive enzymes. Examples of proteins ([@BIB12], [@BIB10]) and carbohydrates ([@BIB9], [@BIB26]) highly resistant to digestive enzymes have been reported. Other examples include IgA and vitamin B12 absorptive factors.

Our studies of antiviral mechanisms allow some limited inferences to be made, even though the GI inhibitors are impure. All these inhibitors neither directly inactivate infectious virions nor induce an antiviral state in the cells. Thus, the inhibition requires the continuous presence of inhibitor with the virus and cells. Possible inhibitory mechanisms include: (1) a low affinity binding of inhibitor to virus or cells, (2) competitive inhibition, and (3) a rapid reversibility of antiviral effects. These possibilities are under study.

The GI inhibitors appear to act at different stages of the multiplication cycle of SBV, as shown by experiments of inhibitory activities at 4°C and addition of inhibitors at different time intervals during a single-cycle of virus multiplication. The mouse intestine preparation appears to prevent virus attachment, because it is active at 4°C, a temperature at which only virus attachment may occur ([Table 3](#TBL3){ref-type="table"}). Consistent with inhibition of virus attachment by the mouse intestinal inhibitor is its very early inhibitory action only when added at 0 h during a single cycle of virus multiplication ([Fig. 1](#FIG1){ref-type="fig"}).

In comparison, neuramide is not active at 4°C ([Table 3](#TBL3){ref-type="table"}), indicating that it acts at a post-attachment stage of virus multiplication. The post-attachment inhibition must be early however, because neuramide loses its inhibitory activity when added 0.5 h post-infection ([Fig. 1](#FIG1){ref-type="fig"}).

The antiviral action of the porcine mucosal inhibitor appears to occur late in the virus multiplication cycle. It does not act at 4°C ([Table 3](#TBL3){ref-type="table"}), indicating that virus attachment is not inhibited. When added as late as 6 h after virus infection, it strongly inhibits virus multiplication, indicating that it acts late in the virus growth cycle. These possible mechanisms of action must eventually be confirmed using purified inhibitors and molecular probes.

Consistent with a defensive role for the GI tract inhibitors is their naturally high titer, broad antiviral activity, including an enterovirus, and location in the GI tract and its lumen. Interestingly, elution or secretion of a distinct viral inhibitor into extracellular fluids has been reported for nervous tissue ([@BIB7]), but has not been found using kidney and liver. To definitely assign defensive roles, future studies should show that (1) administration of these inhibitors is protective in vivo and (2) deletion of the inhibitors enhances infections.

If the GI inhibitors are host defense mechanisms then we may speculate that they may eventually be medically applicable. Such possible medical application may be made more likely by the small size of these inhibitors, which may make their synthesis more practical and also result in less antigenicity.

The present characterization of GI inhibitors allows comparison of properties of all the broadly-active antiviral innate substances reported in body fluids and tissues ([@BIB1], [@BIB4], [@BIB5], [@BIB17], [@BIB20], [@BIB21], [@BIB22]) ([Table 4](#TBL4){ref-type="table"} ). As shown in the first column of [Table 4](#TBL4){ref-type="table"}, broadly active antiviral substances are present in the plasma, nervous system, and GI tract. However, they differ in size, chemical structure, and mechanism of action. As shown in the third column, the GI inhibitors are relatively small (0.6 kDa) compared to the large molecular complexes in plasma (60 and 500 kDa) and the nervous system (4000 kDa). Interestingly, the 60 kDa molecular weight inhibitor in the plasma (UTIβ) and the 4000 kDa inhibitor in the nervous system (NS) can be broken down into active smaller size inhibitors (≤1 kDa) similar in size to the GI inhibitors ([@BIB7], [@BIB20], [@BIB21]). In addition, both small peptides and apolipoprotein A-1 from the HDL retain some antiviral activity ([@BIB24]). Thus, smaller molecular components of the larger inhibitors appear to be inhibitory.Table 4Properties of broadly antiviral innate substancesLocation in situInhibitor designationSize (kDa)Antiviral conc. range (U/ml)Chemical structureMode of antiviral actionReferenceTotalAntiviralPlasmaUTIβ6024--155GlycoproteinCarbohydratePrevents attachment[@BIB12]PlasmaHDL5004--6LipoproteinProteinPost penetration[@BIB15], [@BIB19]Nervous systemNS400036--288Lipo-glycopro-tein complexProtein and carbohydratePrevents attachment[@BIB13]IntestineIntestinal lumen and tissues0.6137--2162Undetermined[a](#TBLFN9){ref-type="table-fn"}Undetermined[a](#TBLFN9){ref-type="table-fn"}Prevents attachment[@BIB9]; see resultsGastric extract and milkNeuramide0.624--64Undetermined[a](#TBLFN9){ref-type="table-fn"}Undetermined[a](#TBLFN9){ref-type="table-fn"}Post attachmentSee resultsGastric tissuesPorcine gastric mucosa0.624--64Undetermined[a](#TBLFN9){ref-type="table-fn"}Undetermined[a](#TBLFN9){ref-type="table-fn"}Post attachmentSee results[^9]

The viral inhibitory assays indicate that all, except HDL, occur in high titers, starting at at least 25 U/ml or g (column 4). These high titers are in the same range as interferon which is an established host defense. The GI inhibitors which have the lowest molecular weight (600 Da) (columns 3), are resistant to lipid extraction, proteolytic and glycolytic enzymatic digestion (columns 5 and 6). On the other hand, the NS inhibitor is a large molecule of 4000 kDa and is inactivated by proteinase and glycosidases. HDL has a molecular size of 500 kDa and a peptide structure appears to be responsible for its antiviral activity. UTIβ is a glycoprotein of 60 kDa with carbohydrate as the antiviral moiety. The mechanism of action (column 7) of the mouse intestinal inhibitor, UTIβ, and the NS inhibitor occurs at the virus stage of attachment. The HDL inhibition is at the stage of virus penetration. Neuramide acts in the early post-attachment phase, and the porcine gastric mucosal preparation acts during the late post-attachment phase.

In conclusion, the innate broad-spectrum antiviral molecules which occur widely in the body tissues and fluids in significant titers, can be considered important as initial barriers to viral infections and thereby, also offer potential for medical use. Future studies are needed for purification and to study the molecular structures, their biosynthesis, mechanism of action, and medical application.
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[^1]: *P*\>0.05 (statistically insignificant) for the different viruses by the Student *t*-test. Results are the average of 4--6 experiments.

[^2]: Viruses: SB (Sindbis), VS (vesicular stomatitis), VAC (vaccinia), Mengo and HSVI (herpes simplex type 1).

[^3]: Clarified and filtered preparations without further purification, were used as described in [Section 2](#SEC2){ref-type="sec"}. Neuramide was adjusted to pH 7.3 and to isotonicity by dialysis with balanced salt solution so that Neuramide would be in the same suspending medium as the other preparations.

[^4]: Antiviral activity was assayed against SB virus and presented as an average of at least two experiments.

[^5]: ND, not done; all differences not different statistically (*P*\>0.05).

[^6]: Average of more than 2--3 experiments.

[^7]: Viruses: SB (Sindbis), VS (vesicular stomatitis) and mengo.

[^8]: Statistically significantly different. *P*\<0.005 using the Student\'s *t*-test comparing 4 and 37°C.

[^9]: Antiviral activity stable after treatment with protease, glycosidases (periodate), and lipid solvents.
